Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of HDT-321 CCHF Vaccine in Healthy Adults
NCT06799013Phase 1Recruiting
- Sponsor
- HDT Bio
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics, RNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of HDT-321 in Crimean–Congo hemorrhagic fever (CCHF) (4 arms), sponsored by HDT Bio. Primary endpoints: Solicited local and systemic adverse events, Unsolicited study product related adverse events and 2 more. Started Jul 2025; status: recruiting.
02
Drugs
HDT-321
03
Conditions
Crimean–Congo hemorrhagic fever (CCHF)
Beyond the preview
Go deeper on NCT06799013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06799013.